REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, a pivotal Open Access journal published by ARAN EDICIONES, S A, has been at the forefront of advancing the field of gastroenterology since its inception in 1990. With a robust commitment to disseminating high-quality research, the journal provides a platform for researchers, clinicians, and students to share innovative findings and insights concerning digestive diseases. The journal is characterized by its Q3 ranking in both Gastroenterology and Miscellaneous Medicine categories, indicative of its significant contributions to these fields, and is positioned within the 36th percentile of Scopus rankings for medicine related to gastroenterology. Based in Spain, REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS has embraced the Open Access model since 2004, ensuring that its articles are readily available to a global audience without financial barriers. The journal not only supports academic discourse but also plays a crucial role in improving clinical practices and health outcomes related to digestive health.

HPB is a premier journal dedicated to advancing the fields of Gastroenterology and Hepatology, published by Elsevier Science Ltd. With an impressive impact factor reflective of its high-quality research output, HPB has earned its place as a Q1 journal in Gastroenterology and Q2 in Hepatology as of 2023. The journal, available in both print and electronic formats (ISSN: 1365-182X; E-ISSN: 1477-2574), serves as a vital platform for multidisciplinary research, encompassing clinical and experimental studies, aimed at improving patient care and outcomes related to liver and biliary diseases. Since its inception in 2000, HPB has published influential articles that have shaped practice and policy in the field. Located in the United Kingdom, at 125 London Wall, London EC2Y 5AS, the journal is poised to continue its mission of fostering innovation and collaboration among researchers, healthcare professionals, and academicians worldwide.

JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.

Gastroenterology, published by W B Saunders Co-Elsevier Inc, is a premier journal dedicated to advancing the knowledge and practice within the fields of gastroenterology and hepatology. Established in 1945 and covering a wide range of topics related to digestive health, this journal holds a distinguished position in the academic community, as evidenced by its impressive Q1 status in both Gastroenterology and Hepatology categories, and its high rankings (4th in both disciplines) in Scopus, placing it in the top percentile for scholarly impact. With its commitment to publishing high-quality research, reviews, and clinical studies, Gastroenterology provides an essential resource for researchers, healthcare professionals, and students seeking cutting-edge insights that inform clinical practices and enhance patient care. Although it does not currently offer open access, the journal continues to serve as a vital platform for disseminating meaningful research that shapes the future of digestive disease management.

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

Hepatology Forum is an esteemed journal dedicated to disseminating cutting-edge research and insights in the fields of gastroenterology and hepatology. Published by KARE PUBL in Turkey, this journal serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to advance their knowledge and practices related to liver diseases and gastrointestinal disorders. With an ISSN of 1307-5888 and an E-ISSN of 2757-7392, it features peer-reviewed articles that encompass a wide range of topics from basic research to clinical applications. Although categorized in the Q3 quartile for both gastroenterology and hepatology in 2023, Hepatology Forum continues to show significant potential for growth and impact, as evidenced by its Scopus rankings. Through its commitment to open scientific exchange, the journal not only facilitates the sharing of innovative methodologies and findings but also fosters networking among professionals in the field. As it converges through the years from 2020 to 2024, Hepatology Forum remains an important resource for the advancement of liver health and diseases, appealing to both established experts and emerging scholars alike.

Clinical Gastroenterology and Hepatology, published by Elsevier Science Inc, stands as a leading journal in the fields of gastroenterology and hepatology. With an ISSN of 1542-3565 and an E-ISSN of 1542-7714, this esteemed publication has earned its place in the top quartile (Q1) of both gastroenterology and hepatology categories as of 2023, ranking 6th out of 167 and 7th out of 82 respectively. The journal aims to disseminate innovative research, clinical studies, and case reports that advance the understanding and treatment of gastrointestinal and liver diseases. Targeted towards researchers, healthcare professionals, and students, it provides crucial insights into emerging therapies and medical advancements. Clinical Gastroenterology and Hepatology is not only a pivotal resource for contemporary gastroenterological research but also fosters collaboration and knowledge-sharing within the medical community. With a converging publication history from 2003 to the present, the journal continues to build on its solid foundation of scientific excellence and relevance.

The Journal of Clinical and Experimental Hepatology, published by Elsevier - Division Reed Elsevier India Pvt Ltd, is a premier platform dedicated to advancing the field of hepatology. With an ISSN of 0973-6883 and an E-ISSN of 2213-3453, this journal has gained recognition for its impactful contributions to both clinical practice and scientific research in the domain of liver health. Ranking in the Q2 quartile for Hepatology in 2023 and positioned at 33rd out of 82 in Scopus’s Hepatology category, it reflects a robust impact factor and a commitment to publishing high-quality, peer-reviewed articles. Researchers, clinicians, and students can engage with a wealth of open-access content covering the latest advancements, challenges, and insights in hepatology, as the journal aims to disseminate knowledge from 2011 through 2025. Join the community of experts as we explore critical developments in the understanding and treatment of liver diseases.

SEMINARS IN LIVER DISEASE is a premier journal dedicated to advancing the field of hepatology, published by THIEME MEDICAL PUBL INC. Established in 1981, it has become a respected resource within the academic community, providing high-quality peer-reviewed articles that cover a broad range of topics related to liver diseases. With an impressive impact factor and recognized as a Q1 journal in the hepatology category, it ranks 17th out of 82 journals in the field, placing it in the top 21% of its category according to Scopus rankings. Although it does not offer open access, the journal’s rigorous standards and extensive network ensure that it reaches a wide audience of clinicians, researchers, and students, fostering knowledge and innovation in liver disease management. The journal's objectives focus on disseminating critical insights and promoting informed discussions that can pave the way for future research and clinical advancements in hepatology.

Hepatology Communications, published by Lippincott Williams & Wilkins, serves as a pioneering platform in the field of hepatology, dedicated to advancing the understanding of liver diseases and treatments. Since its inception in 2017, this open access journal has rapidly gained recognition, achieving an impressive Q1 ranking in Hepatology as of 2023, and appealing to a diverse audience of researchers, clinicians, and students alike. With its focus on high-quality research and clinical studies, the journal aims to facilitate impactful discussions and disseminate vital findings that address the challenges faced in liver health. Operating out of the United States, and accessible globally, Hepatology Communications is committed to fostering a collaborative research environment and enhancing the visibility of scholarly work in hepatology, ultimately driving forward innovations in patient care and treatment strategies.